Galectin Therapeutics Inc.
GALT
$1.37
$0.032.24%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -1.35% | -5.76% | -7.68% | -4.59% | -10.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.45% | 1.08% | 4.11% | -3.56% | -0.73% |
| Operating Income | -11.45% | -1.08% | -4.11% | 3.56% | 0.73% |
| Income Before Tax | -14.56% | -8.09% | -11.07% | -1.63% | -5.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.56% | -8.09% | -11.07% | -1.63% | -5.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.56% | -8.09% | -11.07% | -1.63% | -5.91% |
| EBIT | -11.45% | -1.08% | -4.11% | 3.56% | 0.73% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.58% | 4.55% | -16.48% | -8.24% | -13.92% |
| Normalized Basic EPS | -10.54% | -3.66% | -7.47% | 0.68% | -4.61% |
| EPS Diluted | -1.61% | 4.52% | -16.51% | -8.24% | -13.92% |
| Normalized Diluted EPS | -10.54% | -3.66% | -7.47% | 0.68% | -4.61% |
| Average Basic Shares Outstanding | 3.57% | 4.27% | 3.32% | 2.29% | 1.29% |
| Average Diluted Shares Outstanding | 3.57% | 4.27% | 3.32% | 2.29% | 1.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |